ACTRN12617000420347.

Study name	Evaluating the effectiveness of practicing yoga during haemodialysis for fatigue in patients with end stage kidney disease
Methods	Study design RCT Duration of follow‐up: 12 weeks
Participants	Study characteristics Country: Australia Setting: multicentre (2 dialysis facilities in Brisbane, Queensland) Inclusion criteria 18 and 80 years, who have been received for a period of greater than 90 days prior to trial entry In‐centre patients with a HD prescription of 3 sessions/week Patients with an arterial venous fistula or graft Patients who are haemodynamically stable, meaning no medical intervention has been needed for hypotensive episodes and use of saline at least 2 weeks prior to trial entry Receive a global fatigue score of ‐4 on the BFI scale Must be competent to understand the research procedures, and provide written informed consent Not currently practicing yoga Exclusion criteria ESKD patients who dialyse at home ESKD patients who are treated with peritoneal dialysis HD patients with catheters, including cuffed tunnelled and non‐cuffed non‐tunnelled catheters HD patients with concomitant conditions that in the opinion of the Chief Investigator may adversely affect the safety and efficacy of the intradialytic yoga intervention, or severely limit the patient’s ability to complete the study
Interventions	Intervention group Intradialytic yoga for 3 sessions/week over 12 weeks Control group Usual care Co‐interventions Not reported
Outcomes	Planned outcomes Change in symptoms of fatigue CFQ: after 12 weeks Change in symptoms of post‐dialysis fatigue recorded by participants Post Dialysis Fatigue Diary: after 12 weeks Change in HRQoL KDQoL‐SF: after 12 weeks Change in potassium level: after 12 weeks Change in level of phosphate: after 12 weeks Change in interdialytic fluid gain: after 12 weeks Changes in biochemical markers (BP, CRP, urea, TSAT, ferritin, creatinine, ALP, intact PTH, albumin, erythrocyte count, HCT, Kt/V, electrolyte): after 12 weeks Feasibility and acceptability and dropout rate Participants’ beliefs about the treatment intervention CEQ: after 12 weeks Adherence to the intervention measured as frequency and duration: after 12 weeks Qualitative feedback from caregivers Adverse events (vascular access dysfunction, hypotensive/hypertensive episodes, muscles cramps, musculoskeletal injuries, cardiovascular events, hospitalisation, deaths): after 12 weeks
Starting date	July 2017
Contact information	Kylie Barr Phone: +61 409 992 262 Email: k.barr@westernsydney.edu.au
Notes	ClinicalTrials.gov Identifier: ACTRN12617000420347. Funding: none. Recruitment status: completed